Effective drug delivery is important in the treatment of various biomedical conditions, ranging from autoimmune disorders to cancer and bacterial infections. Nanostructured systems can help to overcome challenges to efficient drug delivery such as poor drug distribution, inefficient penetration across biological barriers and off-target effects. The bioinspired nanotopography of drug carrier surfaces provides a physical cue to modulate their interaction with biological systems. In this Review, we discuss how naturally occurring nanotopographical systems can inspire the design of biomaterials for drug delivery. We highlight nanoscale surface modifications of drug carriers and fabrication strategies, followed by a discussion about nanotopographical biointerfaces to regulate biological functions. Key bioinspired nanotopographical functionalities include bio-adhesion, barrier remodelling, drug uptake and subcellular trafficking, cellular signalling and modulation, and antimicrobial interfaces. Finally, we provide an outlook on the future of nanotopographical applications in drug delivery, with a focus on key challenges and exciting opportunities from bench to bedside.
Glioblastoma is a particularly challenging cancer, as there are currently limited options for treatment. New delivery routes are being explored, including direct intratumoral injection via convection-enhanced delivery (CED). While promising, convection-enhanced delivery of traditional chemotherapeutics such as doxorubicin (DOX) has seen limited success. Several studies have demonstrated that attaching a drug to polymeric nanoscale materials can improve drug delivery efficacy via CED. We therefore set out to evaluate a panel of morphologically distinct protein nanoparticles for their potential as CED drug delivery vehicles for glioblastoma treatment. The panel consisted of three different virus-like particles (VLPs), MS2 spheres, tobacco mosaic virus (TMV) disks and nanophage filamentous rods modified with DOX. While all three VLPs displayed adequate drug delivery and cell uptake in vitro, increased survival rates were only observed for glioma-bearing mice that were treated via CED with TMV disks and MS2 spheres conjugated to doxorubicin, with TMV-treated mice showing the best response. Importantly, these improved survival rates were observed after only a single VLP–DOX CED injection several orders of magnitude smaller than traditional IV doses. Overall, this study underscores the potential of nanoscale chemotherapeutic CED using virus-like particles and illustrates the need for further studies into how the overall morphology of VLPs influences their drug delivery properties.
We report a CB6 rotaxane for the 129Xe hyperCEST NMR detection of matrix metalloprotease 2 (MMP-2) activity. MMP-2 is overexpressed in cancer tissue, and hence is a cancer marker. A peptide containing an MMP-2 recognition sequence was incorporated into the rotaxane, synthesized via CB6-promoted click chemistry. Upon cleavage of the rotaxane by MMP-2, CB6 became accessible for 129Xe@CB6 interactions, leading to protease-responsive hyperCEST activation.
Bacterial biofilm infections, particularly those of Pseudomonas aeruginosa (PA), have high rates of antimicrobial tolerance and are commonly found in chronic wound and cystic fibrosis lung infections. Combination therapeutics that act synergistically can overcome antimicrobial tolerance; however, the delivery of multiple therapeutics at relevant dosages remains a challenge. We therefore developed a nanoscale drug carrier for antimicrobial codelivery by combining approaches from polyelectrolyte nanocomplex (NC) formation and layer-by-layer electrostatic self-assembly. This strategy led to NC drug carriers loaded with tobramycin antibiotics and antimicrobial silver nanoparticles (AgTob-NCs). AgTob-NCs displayed synergistic enhancements in antimicrobial activity against both planktonic and biofilm PA cultures, with positively charged NCs outperforming negatively charged formulations. NCs were evaluated in mouse models of lung infection, leading to reduced bacterial burden and improved survival outcomes. This approach therefore shows promise for nanoscale therapeutic codelivery to treat recalcitrant bacterial infections.
Bacteria-based therapies such as live biotherapeutic products (LBPs) allow for the in situ production of bioactive and therapeutic compounds, offering immense potential in the treatment of numerous diseases, including colitis, cancer, and metabolic diseases. While promising, LBPs face numerous delivery barriers that limit their translational potential. Many of these challenges stem from the specific requirements of delivering living bacteria, necessitating delivery systems with distinctive features beyond traditional drug delivery approaches. By taking inspiration from natural biological systems such as bacterial membranes, capsules, and biofilms, researchers can build upon fundamental biological insights combined with advances in materials science, chemical biology, and bioengineering to develop next-generation LBP delivery systems. In this review, we will cover the current progress in bacterial LBPs and major barriers to their delivery. We will then discuss in depth the different bioinspired LBP delivery systems that have been developed and highlight challenges that must be addressed for this nascent field to advance and achieve widespread clinical translation.
15 September 2020 in Advanced Functional Materials